Mestinon (Pyridostigmine) is an acetylcholinesterase inhibitor used to treat myasthenia gravis and Sjögren's syndrome. It inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, resulting in higher circulating levels of the neurotransmitter. It cannot cross the blood brain barrier, and so only works on the peripheral nervous system.
Mestinon and M.E.[edit | edit source]
Anecdotal patient reports of Mestinon are mixed.
Interviews[edit | edit source]
- 2018, Advancements in ME/CFS Research, David M. Systrom, MD; Brigham and Women's Hospital | ME/CFSAlert 98 (David Systrom, confirming some positive clinical results and plans for a clinical trial)
Learn more[edit | edit source]
- Wikipedia - Pyridostigmine
- "Mestinon for ME", Living With Chronic Fatigue Syndrome blog post, September 13, 2017
- "A Mestinon Miracle: Vagus Nerve Stimulating Drug Helps Long Time ME/CFS Patient Exercise", Health Rising Blog, June 17, 2016
References[edit | edit source]
- Oliveira, R.K. (2016). "Pyridostigmine for Exercise Intolerance Treatment in Preload Failure". American Journal of Respiratory and Critical Care Medicine.